Table 1.
Endocrine IRAEs in patients treated with ipilimumab
| Study | Cohort | Endocrinopathy | ||||||
|---|---|---|---|---|---|---|---|---|
| Age (range) | n | Hypophysitis | 2°/Other AI | 2°/Other HT | 1° HT | Thyroiditis | 1° AI | |
| Phan, et al(2003)64 | 52 (39–67) | 14 | 1 | 1 | 1 | NR | NR | NR |
| Attia, et al(2005)82 | 50.1 (21–67) | 56 | 1 | NR | NR | NR | NR | NR |
| Maker, et al(2006)62 | 48 (24–68) | 46 | 8 | NR | 1* | NR | NR | NR |
| Downey, et al(2007)86 | 50 (21–69) | 139 | 13 | NR | 3* | NR | NR | NR |
| Small, et al(2007)89 | 70.5 (56–79) | 14 | NR | NR | NR | NR | NR | NR |
| Yang, et al(2007)39 | 52–59 (31–70) | 61 | 2 | 1* | NR | NR | NR | NR |
| Weber, et al(2008)90 | 59 (29–87) | 88 | NR | 1* | NR | NR | NR | NR |
| Ansell, et al(2009)91 | 56 (37–79) | 18 | 1 | NR | NR | NR | NR | NR |
| O’Day, et al(2010)92# | 59 (26–85) | 155 | NR | NR | NR | NR | NR | NR |
| Hodi, et al(2010)7 | 55.6–56.8|| | 540 | 4 | 5* | 8* | NR | NR | NR |
| Hersh, et al(2011)93 | 61 (25–82) | 72 | NR | 1* | NR | NR | NR | NR |
| Ku et al (2010)87 | 62 (38–86) | 53 | 1ǂ | 2 | 1* | NR | NR | NR |
| Royal, et al(2010)94 | 55 (27–68) | 27 | 1 | NR | NR | NR | NR | NR |
| Robert, et al(2011)8 | 57.5|| | 250 | NR | NR | NR | NR | NR | NR |
| DiGiacomo, et al(2011)95 | 55 (23–77) | 27 | NR | NR | 2* | NR | 1 | NR |
| Eggermont, et al(2015)88 | 51 (20–84) | 475 | 86 | NR | 42* | NR | NR | NR |
| Faje, et al(2014)36† | 59.9–68.2|| | 154 | 17ǂ | 7 | 17 | 8 | NR | NR |
| Ryder, et al(2014)32†** | NR | 256 | 19 | 16 | 11 | 15 | 8 | 2 |
| Postow, et al(2015)131 | 67 (31–80) | 47 | 3 | 2* | 7* | NR | NR | NR |
| Larkin, et al(2015)132 | 61 (18–89) | 315 | 12 | NR | 13* | NR | NR | NR |
| Albarel, et al(2015)48†## | 55.5|| | 131 | 15 | 11 | 13 | NR | NR | NR |
| Total | 2938 | 184 (9.1%) | 37 (6.1%) | 42 (7.6%) | 23 (5.6%) | 9 (3.2%) | 2 (0.8%) | |
| Event/Totalǂǂ | - | 184/2017 | 37/608|||| | 42/555|||| | 23/410 | 9/283 | 2/256 | |
*
Unclear etiology (such as primary versus secondary)
#
Endocrinopathies (n=9) reported but no specifics given
ǂ
Single patient within trial cohort with multiple events (hypophysitis)
||
Age range not given;
†
Retrospective review.
**
18 patients had secondary gondadotroph deficiency.
##
12 patients had secondary gondadotroph deficiency.
ǂǂ
Percentage determined by total number of events divided from total number of patients only from studies reporting event.
||||
Unclear etiologies were not included in calculation.
AI, adrenal insufficency; HT, hypothyroidism; NR, not reported
Note: Secondary gonadotroph deficiency was reported in 30 out of 401 patients (7.5%)